Acuvi Q2’22: Initial take - Redeye

Redeye was hoping for a little more in terms of top-line growth. Sales in Q2 grew by 14% proforma, which is a bit lower than previous quarters. COGS and other cost items, adjusted for one-offs, are basically as expected. Management’s outlook is clearly optimistic and anticipate higher business activity and a stronger second half of 2022. We will most likely make some downward adjustments to our near-term forecasts.

Länk till analysen i sin helhet: https://www.redeye.se/research/852808/acuvi-q222-initial-take?utm_source=finwire&utm_medium=RSS